Skip to main content
Erschienen in: Clinical Rheumatology 7/2017

09.05.2017 | Case Based Review

Recurrent infections in a patient with psoriatic arthritis and hypogammaglobulinemia, treated with conventional and biologic disease-modifying anti-rheumatic drugs—a primary or secondary entity?

verfasst von: Ewa Więsik-Szewczyk, Aleksandra Kucharczyk, Katarzyna Świerkocka, Elżbieta Rutkowska, Karina Jahnz-Różyk

Erschienen in: Clinical Rheumatology | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Abstract

A 54-year-old man with confirmed psoriatic arthritis, treated with conventional and biologic disease-modifying anti-rheumatic drugs, suffered from severe, recurrent respiratory tract infections. He was found to have hypogammaglobulinemia. Further investigations confirmed the diagnosis of common variable immunodeficiency. Introduction of immunoglobulin G replacement therapy allowed for safe and effective treatment of psoriatic arthritis with etanercept and methotrexate. Patients with a history of recurrent infections on disease-modifying anti-rheumatic drugs and hypogammaglobulinemia should be assessed for primary antibody immunodeficiencies, even in adulthood.
Literatur
1.
Zurück zum Zitat Hagberg KW, Li L, Peng M, Paris M, Shah K, Jick SS (2016) Rates of cancers and opportunistic infections in patients with psoriatic arthritis compared with patients without psoriatic arthritis. J Clin Rheumatol 22:241–247CrossRefPubMedPubMedCentral Hagberg KW, Li L, Peng M, Paris M, Shah K, Jick SS (2016) Rates of cancers and opportunistic infections in patients with psoriatic arthritis compared with patients without psoriatic arthritis. J Clin Rheumatol 22:241–247CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Haroon N, Inman RD (2009) Infectious complications of biological therapy. Curr Opin Rheumatol 21:397–403CrossRefPubMed Haroon N, Inman RD (2009) Infectious complications of biological therapy. Curr Opin Rheumatol 21:397–403CrossRefPubMed
3.
Zurück zum Zitat Furst DE (2009) Serum immunoglobulins and risk of infection: how low can you go? Semin Arthritis Rheum 39:18–29CrossRefPubMed Furst DE (2009) Serum immunoglobulins and risk of infection: how low can you go? Semin Arthritis Rheum 39:18–29CrossRefPubMed
4.
Zurück zum Zitat Blot M, Boyer P, Samson M et al (2014) Should mild hypogammaglobulinemia be managed as severe hypogammaglobulinemia? A study of 389 patients with secondary hypogammaglobulinemia. Eur J Intern Med 25:837–842CrossRefPubMed Blot M, Boyer P, Samson M et al (2014) Should mild hypogammaglobulinemia be managed as severe hypogammaglobulinemia? A study of 389 patients with secondary hypogammaglobulinemia. Eur J Intern Med 25:837–842CrossRefPubMed
5.
Zurück zum Zitat Samson M, Audia S, Lakomy D, Bonnotte B, Tavernier C, Ornetti P (2011) Diagnostic strategy for patients with hypogammaglobulinemia in rheumatology. Joint Bone Spine 78:241–245CrossRefPubMed Samson M, Audia S, Lakomy D, Bonnotte B, Tavernier C, Ornetti P (2011) Diagnostic strategy for patients with hypogammaglobulinemia in rheumatology. Joint Bone Spine 78:241–245CrossRefPubMed
6.
Zurück zum Zitat Chapel H, Lucas M, Lee M, Bjorkander J, Webster D, Grimbacher B, Fieschi C, Thorn V, Abedi MR, Hammarstrom L (2008) Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 112:277–286CrossRefPubMed Chapel H, Lucas M, Lee M, Bjorkander J, Webster D, Grimbacher B, Fieschi C, Thorn V, Abedi MR, Hammarstrom L (2008) Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 112:277–286CrossRefPubMed
7.
Zurück zum Zitat Gathmann B, Mahlaoui N, CEREDIH et al (2014) Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol 134:116–126CrossRefPubMed Gathmann B, Mahlaoui N, CEREDIH et al (2014) Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol 134:116–126CrossRefPubMed
8.
Zurück zum Zitat ESID Working Definitions for diagnosis of PID. file:///C:/Users/Samsung/Downloads/ESIDRegistry_ClinicalCriteria%20(5).pdf ESID Working Definitions for diagnosis of PID. file:///C:/Users/Samsung/Downloads/ESIDRegistry_ClinicalCriteria%20(5).pdf
9.
Zurück zum Zitat Bonilla FA, Barlan I, Chapel H et al (2016) International Consensus Document (ICON): common variable immunodeficiency disorders. J Allergy Clin Immunol Pract 4:38–59CrossRefPubMed Bonilla FA, Barlan I, Chapel H et al (2016) International Consensus Document (ICON): common variable immunodeficiency disorders. J Allergy Clin Immunol Pract 4:38–59CrossRefPubMed
10.
Zurück zum Zitat Wirsum C, Glaser C, Gutenberger S et al (2016) Secondary antibody deficiency in glucocorticoid therapy clearly differs from primary antibody deficiency. J Clin Immunol 36:406–412CrossRefPubMed Wirsum C, Glaser C, Gutenberger S et al (2016) Secondary antibody deficiency in glucocorticoid therapy clearly differs from primary antibody deficiency. J Clin Immunol 36:406–412CrossRefPubMed
11.
Zurück zum Zitat Makatsori M, Kiani-Alikhan S, Manson AL et al (2014) Hypogammaglobulinaemia after rituximab treatment—incidence and outcomes. QJM 107:821–828CrossRefPubMed Makatsori M, Kiani-Alikhan S, Manson AL et al (2014) Hypogammaglobulinaemia after rituximab treatment—incidence and outcomes. QJM 107:821–828CrossRefPubMed
12.
Zurück zum Zitat Boileau J, Mouillot G, Gerard L et al (2011) Autoimmunity in common variable immunodeficiency: correlation with lymphocyte phenotype in the French DEFI study. J Autoimmun 36:25–32CrossRefPubMed Boileau J, Mouillot G, Gerard L et al (2011) Autoimmunity in common variable immunodeficiency: correlation with lymphocyte phenotype in the French DEFI study. J Autoimmun 36:25–32CrossRefPubMed
13.
Zurück zum Zitat Sordet C, Cantagrel A, Schaeverbeke T, Sibilia J (2005) Bone and joint disease associated with primary immune deficiencies. Joint Bone Spine 72:503–514CrossRefPubMed Sordet C, Cantagrel A, Schaeverbeke T, Sibilia J (2005) Bone and joint disease associated with primary immune deficiencies. Joint Bone Spine 72:503–514CrossRefPubMed
14.
Zurück zum Zitat Swierkot J, Lewandowicz-Uszynska A, Chlebicki A, Szmyrka-Kaczmarek M, Polańska B, Jankowski A, Szechiński J (2006) Rheumatoid arthritis in a patient with common variable immunodeficiency: difficulty in diagnosis and therapy. Clin Rheumatol 25:92–94CrossRefPubMed Swierkot J, Lewandowicz-Uszynska A, Chlebicki A, Szmyrka-Kaczmarek M, Polańska B, Jankowski A, Szechiński J (2006) Rheumatoid arthritis in a patient with common variable immunodeficiency: difficulty in diagnosis and therapy. Clin Rheumatol 25:92–94CrossRefPubMed
15.
Zurück zum Zitat Lin LH, Tsai CN, Liu MF, Wang CR (2005) Common variable immunodeficiency mimicking rheumatoid arthritis with Sjögren’s syndrome. J Microbiol Immunol Infect 38:358–360PubMed Lin LH, Tsai CN, Liu MF, Wang CR (2005) Common variable immunodeficiency mimicking rheumatoid arthritis with Sjögren’s syndrome. J Microbiol Immunol Infect 38:358–360PubMed
16.
Zurück zum Zitat Diamantopoulos AP, Haugeberg G (2012) Recurrent infections in a rheumatoid arthritis patient with a primary immunodeficiency, treated with conventional and biologic disease-modifying anti-rheumatic drugs. Mod Rheumatol 22:295–297CrossRefPubMed Diamantopoulos AP, Haugeberg G (2012) Recurrent infections in a rheumatoid arthritis patient with a primary immunodeficiency, treated with conventional and biologic disease-modifying anti-rheumatic drugs. Mod Rheumatol 22:295–297CrossRefPubMed
17.
Zurück zum Zitat Xiao X, Miao Q, Chang C, Gershwin ME, Ma X (2014) Common variable immunodeficiency and autoimmunity—an inconvenient truth. Autoimmun Rev 13:858–864CrossRefPubMed Xiao X, Miao Q, Chang C, Gershwin ME, Ma X (2014) Common variable immunodeficiency and autoimmunity—an inconvenient truth. Autoimmun Rev 13:858–864CrossRefPubMed
18.
Zurück zum Zitat Dimitriades VR, Sorensen R (2016) Rheumatologic manifestations of primary immunodeficiency diseases. Clin Rheumatol 35:843–850CrossRefPubMed Dimitriades VR, Sorensen R (2016) Rheumatologic manifestations of primary immunodeficiency diseases. Clin Rheumatol 35:843–850CrossRefPubMed
19.
Zurück zum Zitat Stiehm ER, Keller MA, Vyas GN (2008) Preparation and use of therapeutic anti-bodies primarily of human origin. Biologicals 36:363–374CrossRefPubMed Stiehm ER, Keller MA, Vyas GN (2008) Preparation and use of therapeutic anti-bodies primarily of human origin. Biologicals 36:363–374CrossRefPubMed
20.
Zurück zum Zitat Bonilla FA (2016) Intravenous and subcutaneous immunoglobulin G replacement therapy. Allergy Asthma Proc 37:426–431CrossRefPubMed Bonilla FA (2016) Intravenous and subcutaneous immunoglobulin G replacement therapy. Allergy Asthma Proc 37:426–431CrossRefPubMed
21.
Zurück zum Zitat Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H (2010) Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 125:1354–1360.e4CrossRefPubMed Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H (2010) Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 125:1354–1360.e4CrossRefPubMed
22.
Zurück zum Zitat Quinti I, Agostini C, Tabolli S, Brunetti G, Cinetto F, Pecoraro A, Spadaro G (2012) Malignancies are the major cause of death in patients with adult onset common variable immunodeficiency. Blood 120:1953–1954CrossRefPubMed Quinti I, Agostini C, Tabolli S, Brunetti G, Cinetto F, Pecoraro A, Spadaro G (2012) Malignancies are the major cause of death in patients with adult onset common variable immunodeficiency. Blood 120:1953–1954CrossRefPubMed
23.
Zurück zum Zitat Ammann EM, Jones MP, Link BK et al (2016) Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy. Blood 127:200–207CrossRefPubMedPubMedCentral Ammann EM, Jones MP, Link BK et al (2016) Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy. Blood 127:200–207CrossRefPubMedPubMedCentral
Metadaten
Titel
Recurrent infections in a patient with psoriatic arthritis and hypogammaglobulinemia, treated with conventional and biologic disease-modifying anti-rheumatic drugs—a primary or secondary entity?
verfasst von
Ewa Więsik-Szewczyk
Aleksandra Kucharczyk
Katarzyna Świerkocka
Elżbieta Rutkowska
Karina Jahnz-Różyk
Publikationsdatum
09.05.2017
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 7/2017
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-017-3670-1

Weitere Artikel der Ausgabe 7/2017

Clinical Rheumatology 7/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.